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Abstract The purpose of this study is to understand the
course of costs over a 2-year period in a cohort of recently
diagnosed fibromyalgia (FM) patients receiving different
treatment strategies. Following the diagnosis, patients were
randomly assigned to a multidisciplinary programme (MD),
aerobic exercise (AE) or usual care (UC) without being aware
of alternative interventions. Time between diagnosis and start
of treatment varied between patients. Resource utilisation,
health care costs and costs for patients and families were col-
lected through cost diaries. Mixed linear model analyses
(MLM) examined the course of costs over time. Linear regres-
sion was used to explore predictors of health care costs in the
post-intervention period. Two hundred three participants,
90 % women, mean (SD) age 41.7 (9.8) years, were included
in the cohort. Intervention costs per patient varied from €864
to 1392 for MD and were €121 for AE. Health care costs
(excluding intervention costs) decreased after diagnosis, but
before the intervention in each group, and increased again
afterwards to the level close to the diagnostic phase. In con-
trast, patient and family costs slightly increased over time in
all groups without initial decrease immediately after diagno-
sis. Annualised health care costs post-intervention varied be-
tween €1872 and 2310 per patient and were predicted by
worse functioning and high health care costs at diagnosis. In
patients with FM, health care costs decreased following the
diagnosis by a rheumatologist. Offering patients a specific
intervention after diagnosis incurred substantial costs while
having only marginal effects on costs.
Keywords Fibromyalgia . Health care costs . Health
resources . Intervention . Utilisation
Introduction
Fibromyalgia (FM) is characterised by chronic widespread
musculoskeletal pain, often accompanied by other clinical
manifestations such as fatigue and stiffness, but also cognitive
dysfunction or mood disorders [1, 2]. FM typically affects
women in working age. The prevalence of FM as reported
among adults in Europe and in the USA varies between 2
and 4 % [3, 4]. While the aetiology of FM is unknown, the
impact for the patient is high in terms of physical and mental
suffering [5]. Moreover, FM is associated with substantial
health resource utilisation and productivity loss, resulting in
considerable societal cost-of-illness [3, 6–8]. In the literature,
the average health care cost of FM varies from €1300–8300
per patient and is comparable or even higher than of rheuma-
toid arthritis (RA) or ankylosing spondylitis (AS) [9, 10].
When taking into account the prevalence of the diseases, how-
ever, the societal burden of FM is higher than that of RA or AS
[11].
Various interventions have been studied, among which
multi-modal non-pharmacological programmes as well as
pharmacological therapies. However, the effectiveness of
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these interventions showed conflicting results [12, 13]. In the
absence of substantial clinical effects, the cost-effectiveness of
interventions in FM is disappointing [14–16]. The importance
of a prompt (and earlier) diagnosis and of immediate
(intensive) intervention are increasingly discussed as potential
opportunities to prevent the development of persistent pain
and long-term dysfunction and therefore might increase effec-
tiveness of interventions [13, 17, 18]. Notwithstanding, only
one randomised controlled trial (RCT) in FM patients showed
that better treatment response was found in patients with a
shorter disease duration [19].
Also, beneficial effects of a diagnosis in itself have been
suggested but results of research, all conducted in claims da-
tabases, are conflicting; two studies showed that a diagnosis of
FM increases costs, primarily attributable to an increased use
of medication [20, 21], while two other studies suggested a
reduction in costs attributable to a decrease in the number of
visits to health care providers [22, 23]. Of interest, the first two
studies were North-American and the latter two European.
The clinical burden of FM and the gaps in available
evidence-based treatment recommendations [24, 25] justify a
continued quest for innovations aimed at improving the out-
comes. Such innovative approaches should first of all show
effectiveness on health outcomes. In the absence of health
improvements, reductions in cost-of-illness of FM through
care innovations can be another reason to adopt health care
innovations.
Previous analyses of a pragmatic trial among patients with
recently diagnosed FM patients showed no consistent differ-
ences in relation to health outcomes between those that re-
ceived a partially individualised multidisciplinary intervention
with aftercare (MD), those receiving aerobic exercise (AE)
and those receiving care as usual (UC) [26]. The present re-
search aims to provide insight in resource utilisation and costs
over 2 years in patients with FM after diagnosis and to under-
stand whether the additional costs of specific interventions
result in lower resource utilisation and costs.
Patients and methods
A two-year cost-analyses of data of an observational study in
which a pragmatic trial was embedded.
Participants
A cohort of 203 consecutive patients that were recently
(<3 months) diagnosed with FM according to the American
College of Rheumatology criteria [1] at one of the
Rheumatology Departments of three Medical Centres in the
South of the Netherlands (Maastricht University Medical
Centre (MUMC), Orbis Medical Centre, Sittard, and Atrium
Medical Centre, Heerlen) were asked to participate in a study,
as they were told, on the natural course of FM. Patients that
consented were randomised to MD (n=108), AE (n=47) or
UC (n=48). Patients assigned to MD or AE were asked again
to consent to participate in the proposed intervention without
being aware of the alternative intervention. The study was
approved by the Medical Ethical Committees of the partici-
pating medical centres. The precise procedures in this prag-
matic trial, registration number ISRCTN32542621, have been
published elsewhere [26].
Interventions
The MD intervention was a two-phased group programme of
1 year. Phase l consisted of a 12-week course (three half days
per week) with two therapy sessions of 1.5 h per day.
Sociotherapy and physiotherapy were given twice per week;
psychotherapy and creative arts therapy were given once per
week. Phase II was an aftercare programme that was provided
over the course of the remaining year and consisted of five
group meetings. In addition, a maximum of seven individual
therapy sessions with one of the therapists could be scheduled
if considered necessary by the therapist and/or the patient. The
AE intervention was a 12-week group course given twice a
week by a trained physiotherapist in a community gym, fol-
lowing recommendations for exercise [27]. The UC group
received ‘care as usual’ that comprised at least individualised
education about FM and lifestyle advice by a rheumatologist
or a specialised rheumatology nurse, but could also include
referral to other interventions such as physiotherapy, or addi-
tional counselling by the rheumatology nurse.
Baseline variables
Demographic characteristics (age, gender, education, work
status) and health status were assessed by means of patient-
reported questionnaires at entry in the observational study.
Health status comprised symptom duration, and the impact
of FM, measured by the Fibromyalgia Impact Questionnaire
(FIQ), that consists of 10 items on health in the past week;
physical functioning, numbers of days feel good, number of
days missed work, interference of symptoms with ability to
activities, pain, fatigue, unrefreshed sleep, stiffness, anxiety
and depression [28]. Each item-score was standardised on a
0–10 scale after which a FIQ-total score (0–100) was calcu-
lated [28].
Cost questionnaires and cost valuation
Self-reported FM-related health care resource use and costs
for patients and their families served as a basis for the cost
analysis and were collected by means of 12 cost diaries over a
total study period of 2 years. In each diary, patients had to
indicate the number of visits to general practitioners (GPs),
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medical specialists, physiotherapists and other paramedical
therapists such as psychologists; the prescribed medication
taken; the kind of assistive devices purchased; and the number
of hours professional home help per week received during the
2 months prior to measurement [29]. Next, patients had to
indicate the frequency with which they had participated in
different types of health activities; the number and type of over
the counter drugs that were purchased; the number of hours
help from spouses, other relatives or paid household help per
week received; and the number of preparedmeals used, during
the 2 months prior to measurement [29].
Health care costs for each category were calculated by
multiplying the number of each resource used with its unit
cost, derived from the Dutch Cost Manual or the
Pharmacotherapeutic compass. If true costs were not avail-
able, market prices or tariffs were used [30–32]. Patient and
family costs were calculated by either multiplying the number
of resources used by costs per unit of the service, e.g. shadow
prices in the case of informal home care, or using the price of
the aid/service as stated by the patient [32]. Finally, total
health care costs and total patient and family costs were
summed. Costs for travel per patient were included in the total
costs for visits to each provider or professional. Total direct
costs were the sum of health care costs and patient and family
costs.
Intervention costs
The time input from all health care providers in the MD or AE
group sessions were the basis for the calculation of the costs of
the interventions. Total costs were calculated by summing the
product of each hour of work by the gross salary per hour for
each professional, augmented with 39 % charges for social
security. As recommended, 45 % charges for overhead, in-
cluding for use of accommodation, were added [32]. Finally,
the total calculated costs for MD or AE were divided by the
mean number of participants per group, resulting in a price per
person per programme. The full intervention costs were con-
sidered for every person that started the interventions, even if
patients did not complete the programmes. Costs for travel
expenses to the sessions per patient were again added to the
total intervention costs. Unit costs for wages and travel were
indexed using the Dutch consumer price index rate for the
value in 2010 (Centraal Bureau voor de Statistiek, Den
Haag, Netherlands, www.cbs.nl) [32]. All cost and monetary
values are presented in the Appendix (Table 4).
Periods of interest
To understand the course of resource utilisation and costs per
patient over time, we distinguished four clinical meaningful
periods; the diagnostic phase representing the 2 months before
referral to the rheumatologists and diagnosis of FM
(diagnosis), the period after the diagnosis but before the inter-
vention (pre-intervention), Phase I of MD, and AE
(intervention) and the period after the intervention (post-inter-
vention). As the start of the MD and AE programme varied in
time among individual patients, the average number of ques-
tionnaires available for the period after the diagnosis but be-
fore the start of the MD or AE programmes varied from 1 to 4,
and after the programmes from 6 to 9, while the main inter-
vention period itself was always represented by one question-
naire. For the UC group, the number of questionnaires for
each period was assigned after matching each subject random-
ly to a participant of the MD or AE group (see Figure 1).
Statistical analysis
Intention-to-treat analyses, in which patients were analysed
from the beginning according to the group in which they were
randomised, were performed. Missing data occurred during
the course of the study (12–30 %), and in order to achieve
complete data, missing data were imputed using a non-
parametric regression forest method [33].
First, mixed linear model analyses (MLM), with a random
intercept, a random slope and an unstructured correlation
structure, were used to assess differences between the inter-
vention groups in the longitudinal course of health care costs
and patient and family costs, with the baseline values of the
dependent variables as covariates in the models.
Next, mean between group differences of the direct costs
in- and excluding intervention costs over the total 2-year pe-
riod were tested using a non-parametric bootstrap method to
obtain 95 % confidence intervals.
Finally, to explore predictors of the health care costs in the
period after the intervention a linear regression analysis on the
square roots transformed costs was performed, entering as
predictors age, symptom duration, educational level, FIQ-
total score and health care costs in the diagnostic phase.
Data imputation was performed using R2.10.1, and all oth-
er analyseswere performed using IBMStatistics SPSS version
20.0.
Results
Baseline characteristics of the patients are presented in
Table 1. The mean age was 41 years, and the majority of
patients were female. Between 13 and 20 % had a high edu-
cational level, and about half of the patients were employed.
The detailed course of health care as well as patient and
family resource utilisation in the three groups is presented in
the Appendix (Table 5). In summary, visits to GPs, medical
specialists, physiotherapists and other paramedical profes-
sionals all decreased in each group after the diagnostic phase
and before the intervention. In the AE group, visits to medical
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specialists and other paramedical professionals further de-
creased during the intervention period whereas visits to the
physiotherapist increased somewhat in theMD and UC group.
The use of formal home help increased in the three groups to
higher levels than in the diagnostic phase. After the interven-
tion, visits to medical specialists, physiotherapists and other
paramedical professionals increased again in each group but
remained lower than in the diagnostic phase for GP and med-
ical specialist visits, and use of medication, while becoming
higher for visits to physiotherapists, paramedical professionals
and use of formal home care. Patient and family costs in-
creased in each group from the diagnostic phase onward, but
the largest increase in costs was seen in attending health ac-
tivities, and in using paid home help or informal care.
Health care costs, excluding intervention costs, decreased
statistically significantly after diagnosis but before the inter-
vention in all groups (Figure 2). During the intervention peri-
od, costs in the AE group tended to decrease further and
remained unchanged in the MD group but showed a statisti-
cally significant increase in the UC group. Post-intervention,
health care costs increased again in all groups, although not
statistically significant in the AE group. In the UC group,
health care costs post-intervention were higher than in the
diagnostic phase. MLM confirmed that time had a different
influence on the course of health care costs in the three groups
with statistically significant differences between the AE and
UC group (F=5.3, p=0.01) (not presented), reflecting a soon-
er increase of costs in the UC group (after the initial similar
decrease). Patient and family costs increased in the three
groups. MLM indicated no statistical significance between
group differences.
Patient and family costs increased in the three groups.
MLM indicated no statistical significance between group
differences.
While the changes in costs incurred by the intervention
were marginal and not statistically significant, the inter-
vention costs were substantial; for MD €864 per person in
phase I and in phase II, the costs varied between €86 and
528 per person depending on the number of individual
contacts. Costs for AE were €121 per person. The
resulting total direct costs per person (with and without
programme costs) over the total observation period after
the diagnostic phase are presented in Table 2. Total direct
costs, including the intervention costs, were highest in
MD. However, between group differences were not statis-
tically significant.
Finally, the 2-monthly health care costs in the post-
intervention period were predicted by a high impact of FM
(FIQ) already at entry in the cohort and by higher health care






















































Fig. 1 Study flowchart and
measurements. MD
multidisciplinary intervention
(N=108), AE aerobic exercise
(N=47),UC usual care (N=48).N
represents the number of patients,
n represents the total number of
questionnaires that were included
in the analyses. In addition, the
number of imputed
questionnaires per period is
presented
Table 1 Characteristics of the
patients at entry into the
observational cohort
MD (n=108) AE (n=47) UC (n=48)
Age, mean (SD) years 41.5 (9.6) 41.0 (9.0) 42.9 (11.0)
Female, % 93.5 100 97.9
Duration FM-related symptoms, mean (SD) years 6.9 (6.2) 6.9 (6.1) 7.1 (6.4)
FIQ-total score (0–100), mean (SD) 64.5 (13.7) 60.0 (12.3) 55.4 (15.1)
Married or cohabiting, % 84.2 85.1 83.4
Educational level, %
- Low 56.7 57.8 38.7
- Medium 30.8 33.3 40.9
- High 12.5 8.9 20.4
Work status, % employed 49.5 55.6 50.0
MD multidisciplinary intervention, AE aerobic exercise, UC usual care, FIQ fibromyalgia impact questionnaire
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Discussion
This article describes the course of resource utilisation and
costs in patients that recently received a diagnosis of FM by
the rheumatologist who offered them, soon thereafter, one of
three interventions (MD, AE and UC) along a randomised
pragmatic trial. While the costs of the MD and AE interven-
tion were substantial, their influence on health care costs and
patient and family costs over time was similar.
The major interest of the paper can be found in the course
of health care utilisation and costs over time which decreased
immediately after the diagnoses, before the MD or AE inter-
vention was started. Since we previously failed to show any
effects of the interventions on different aspects of health, in-
cluding the 5-dimensional EuroQol (EQ-5D) [34] and FIQ as
reported in our previous publication [26], a cost-minimisation
study of the pragmatic trial could have been considered.
However, a classical cost-minimisation study starts from the
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Fig. 2 The course of health care costs and patient and family costs per 2 months, averaged over the period. The figure presents median, IQR, range and
outliers. MD multidisciplinary intervention, AE aerobic exercise, UC usual care
Table 2 Costs in € per patient over the total 2 years after the diagnostic phase
Costs Group
UC MD AE Mean difference
MD vs UC (CI)a
Mean difference
AE vs UC (CI)a
Mean difference
MD vs AE (CI)aMean, median (IQR) Mean, median (IQR) Mean, median (IQR)
Health care costs 3800, 3625 (1681, 5788) 3510, 3151 (1204, 5294) 3594, 3337 (1990, 5103) −290 (−1134, 605) −206 (−1207, 806) −84 (−855, 892)
Patient and family
costs




4252, 3973 (2054, 6488) 4075, 3766 (1872, 6167) 4272, 3725 (2127, 5788) −177 (−1095, 767) 20 (−1067, 1158) −197 (−815, 1106)
Including
intervention costs
4252, 3973 (2054, 6488) 4740, 4510 (2248, 6651) 4321, 3725 (2127, 5788) 488 (−418, 1458) 69 (−1025, 1202) 419 (−1370, 479)
MD multidisciplinary intervention, AE aerobic exercise, UC usual care
aMean difference: bootstrapped mean difference (95 % confidence interval)
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intervention onward and would have ignored the course of the
costs incurred during diagnosis and therefore would have
failed to show the large decrease in health care costs after
the diagnostic phase and before the start of a specific interven-
tion. We considered this observation remarkable and decided
to present the evolution of costs from entry into the cohort and
not from the start of the intervention only.
The higher health care costs around the period of diagnosis
likely reflect the high needs of patients to find help for their
complaints. It is understandable that GPs first explore several
diagnostic and treatment options in such periods and next refer
patients, if complaints persist, to a rheumatologist for confirma-
tion of the diagnosis and for a better treatment plan. In addition,
the diagnosis itself includes several consultations and therefore
costs are higher in this period as in FM, follow-up visits are
limited. The decrease in costs after the diagnosis could partially
be attributed to regression to the mean. Notwithstanding, it can-
not be excluded that also the diagnosis itself reassures patients
and reduces resource utilisation in the period short after diagno-
sis and before the start of the MD or AE programme [23, 35].
The increase in patient and family costs, reflecting increased
participation in health activities, and increased use of paid help
and informal care over time is not surprising. In the usual care
setting, patients receive information and education from the
rheumatologist, the rheumatology nurse or the GP and they
are encouraged to implement sports, to pace their tasks and
activities and ask for support from relatives and friends [36,
37]. Our findings confirm adherence to such lifestyle advices.
Our results have far reaching consequences for clinical
practice which is a strength of our study, as it suggests that
care as usual in the Netherlands is as good and substantially
cheaper compared to more complex interventions and might
be appropriate for many patients.
However, some limitations need to be addressed. First, we
have used data from a cohort of patients participating in a trial
and missing data occurred within the cohort. Missing data were
carefully explored and were imputed. Of course, some level of
uncertainty cannot be excluded but the advanced method that
was used for the data imputation limits errors and contributes to
valid data. Also, we did not include indirect costs in our study.
Only 50 % of the patients were employed, and this small sam-
ple would limit the possibility for a reliable assessment of the
course of costs due to productivity loss. Further, our study
comprised a cohort of recently diagnosed patients but in the
cohort, there was not necessarily a recent onset of FM. Likely,
patients had been managed by their GPs during a longer period.
Well-trained GPs in the Netherlands can diagnose and manage
FM appropriately [38], but it is recognised that some GPs avoid
mentioning the diagnosis FM for several reasons. Apparently, a
number of patients raise concerns about the exact diagnosis and
about the treatment options and these patients can be referred to
a rheumatologist. Finally, with regard to the generalisability, it
should be emphasised that patients were referred by GPs and
therefore might present the somewhat more severe spectrum of
the disease. In addition, patients agreeing to participate in the
active interventions might have been already more motivated.
The central role of the GP in referral, the attitude of persons
towards self-management and the content of usual care might
be different across countries and cultures and, therefore, it can-
not be excluded that this intervention might be more (cost-)
effective in other countries of health care settings.
In summary, our results show that after diagnosing FM, the
use of health care resources decreases, and the slight increase
afterwards is largely independent of the interventions offered.
Given the absence of beneficial health effects but additional
high intervention costs of MD and AE, such interventions can-
not be recommended to all patients with FM. Notwithstanding,
we cannot exclude that a subgroup of patients might have ben-
efit from MD or AE; an appropriate selection of patients for
interventions may result in larger effects and may contribute to
cost-effectiveness. Future research should focus on improved
selection of patients for specific health care innovations.
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p value 95.0 % confidence interval (CI) for B
B Standard error Beta Lower bound Upper bound
(Constant) 6.7 3.7 0.07 −0.595 14.065
FIQ-total score 0.093 0.038 0.173 0.01 0.019 0.167
Health care costs 0.004 0.001 0.187 0.01 0.001 0.007
Age 0.080 0.054 0.104 0.14 −0.025 0.186
Duration symptoms 0.117 0.083 0.096 0.16 −0.046 0.281
Education −0.861 0.760 −0.080 0.26 −2.361 0.638
R2 11.9 %; dependent variable: square root transformed health care costs post-treatment
FIQ fibromyalgia impact questionnaire
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Appendix
Table 4 Cost categories, units
and sources of estimate, costs in
Euro (€) per unit (including
travelling expenses)
Cost category Source of estimate Costs per unit, € (2010)
Interventions
Multidisciplinary programme
Phase I: programme Hakkaart-van Roijen, calculated [32] 863.94/programme
Phase II: aftercare Hakkaart-van Roijen, calculated [32] 85.79/programme
Individual sociotherapy Hakkaart-van Roijen, calculated [32] 50.23/contact
Individual creative therapy Hakkaart-van Roijen, calculated [32] 50.23/contact
Individual psychotherapy Hakkaart-van Roijen, calculated [32] 63.17/contact
Aerobic exercise Hakkaart-van Roijen, calculated [32] 120.47/programme
Health care costs
General practitioner
Practice Hakkaart-van Roijen [32] 31.58/contact
Home visits Hakkaart-van Roijen [32] 43.56/contact
Telephone Hakkaart-van Roijen [32] 14.18/contact
Out of hours services, practice Hakkaart-van Roijen [32] 67.42/contact
out of hours services, telephone Hakkaart-van Roijen [32] 26.26/contact
Medical specialist outpatient service
Academic Hakkaart-van Roijen [32] 135.08/contact
Not academic Hakkaart-van Roijen [32] 69.23/contact
Paramedical professionals
Physiotherapy Hakkaart-van Roijen [32] 39.91/contact
Cesar or Mensendieck therapy Hakkaart-van Roijen [32] 38.90/contact
Occupational therapy Hakkaart-van Roijen [32] 38.90/contact
Social work Hakkaart-van Roijen [32] 69.29/contact
Activity therapy Hakkaart-van Roijen, calculated [32]a 19.90/contact
Psychotherapy Hakkaart-van Roijen [32] 82.96/contact
Other Patient-reported costs Various/contact
Prescribed medications Pharmacotherapeutic compass 2007 [30] Various/DDDb
Assistive devices Estimated market pricec Various
Professional home help Hours [32] 24.31/h
Patient and family costs
Health activities Patient-reported costs Various
Over the counter medications Patient-reported costs Various
Prepared meals Estimated market price 7.26/meal
Paid home help Patient-reported costs Various/h
Informal care Hakkaart-van Roijen [32] 12.66/h
a Group session, based on costs for social work: costs individual session/4
bDDD: daily defined dosage
c Various websites: www.thuiszorgwinkel.nl, www.groenekruisdomicurazorg.nl, www.medireva.nl
Table 5 Health care and patient and family resource use per patient in each of the observation periods




GP MD 2.3 (0.0, 3.0) 1.0 (0.0, 1.3) 1.2 (0.0, 1.8) 1.1 (0.3, 1.6)
AE 3.3 (0.0, 2.0) 1.0 (0.0, 1.5) 2.1 (0.0, 2.5) 1.2 (0.4, 1.7)
UC 1.4 (0.0, 2.0) 0.4 (0.0, 0.5) 0.5 (0.0, 0.5) 0.8 (0.3, 1.1)
Medical specialists MD 2.0 (1.0, 2.0) 0.3 (0.0, 0.4) 0.2 (0.0, 0.2) 0.5 (0.0, 1.0)
AE 1.9 (1.0, 2.0) 0.4 (0.0, 0.5) 0.2 (0.0, 0.2) 0.8 (0.1, 1.6)
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